*This is required by the Florida Medical Marijuana Registry System in order to verify your residency. This is not saved or shared with anyone. Failure to provide this will delay your application.
I hereby give permission to the person(s) listed below to receive information about the care of the above-named patient.
I certify that I have been made aware of Compassionate Healthcare of Florida’s Notice of Privacy Practices and that I have a right to receive a copy upon request. This Notice describes the type of uses and disclosures of my protected health information that might occur during my treatment, to facilitate the payment of my bills or in the performance of Compassionate Healthcare of Florida’s health care operations. The Notice also describes my rights and Compassionate Healthcare of Florida’s duties with respect to my protected health information. I understand that copies of the Notice of Privacy Practices are available in the registration areas of each facility. I may request that a copy be mailed to me by calling the office.
Compassionate Healthcare of Florida reserves the right to change the privacy practices that are described in the Notice of Privacy Practices. I may obtain a revised Notice of Privacy Practices by calling the office and requesting a revised copy be mailed to me, by asking for one at the time of my next appointment, or by accessing Compassionate Healthcare of Florida’s web site at flmmjhealth.com to view the most current version.
A qualified physician may not delegate the responsibility of obtaining written informed consent to another person. The qualified patient, or the patient's parent or legal guardian if the patient is a minor, must initial each section of this consent form to indicate that the physician explained the information and, along with the qualified physician, must sign and date the informed consent form.
This consent form contains four parts. Part A must be completed by all patients. Part B is ONLY required for patients under the age of 18 with a diagnosed terminal condition who receive a certification for medical marijuana in a smokable form. Part C is for the smokable route of marijuana. Part D is the signature block and must be completed by all patients.
a. The Federal Government's classification of marijuana as a Schedule I controlled substance.
Potential side effects from the use of marijuana include, but are not limited to, the following: dizziness, anxiety, confusion, sedation, low blood pressure, impairment of short term memory, euphoria, difficulty in completing complex tasks, suppression of the body's immune system, may affect the production of sex hormones that lead to adverse effects, inability to concentrate, impaired motor skills, paranoia, psychotic symptoms, general apathy, depression and/or restlessness. Marijuana may exacerbate schizophrenia in persons predisposed to that disorder. In addition, the use of medical marijuana may cause me to talk or eat in excess, alter my perception of time and space and impair my judgment. Many medical authorities claim that use of medical marijuana, especially by persons younger than 25, can result in long‐term problems with attention, memory, learning, drug abuse, and schizophrenia.
There is substantial evidence of a statistical association between long‐term cannabis smoking and
worsening respiratory symptoms and more frequent chronic bronchitis episodes. Smoking
marijuana is associated with large airway inflammation, increased airway resistance, and lung
hyperinflation. Smoking cannabis, much like smoking tobacco, can introduce levels of volatile
chemicals and tar in the lungs that may raise concerns about the risk of cancer and lung disease.
There is insufficient evidence to support or refute the conclusion that cannabinoids are an effective treatment for cancers, including glioma.
There is evidence to suggest that cannabinoids (and the endocannabinoid system more generally) may play a role in the cancer regulation processes. Due to a lack of recent, high quality reviews, a research gap exists concerning the effectiveness of cannabis or cannabinoids in treating cancer in general.
There is conclusive evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy‐induced nausea and vomiting.
There is insufficient evidence to support or refute the conclusion that cannabinoids are an effective treatment for cancer‐associated anorexia‐cachexia syndrome and anorexia nervosa.
There is insufficient evidence to support or refute the conclusion that cannabinoids are an effective treatment for epilepsy.
Recent systematic reviews were unable to identify any randomized controlled trials evaluating the efficacy of cannabinoids for the treatment of epilepsy. Currently available clinical data therefore consist solely of uncontrolled case series, which do not provide high‐quality evidence of efficacy. Randomized trials of the efficacy of cannabidiol for different forms of epilepsy have been completed and await publication.
There is limited evidence that cannabinoids are an ineffective treatment for improving intraocular pressure associated with glaucoma.
Lower intraocular pressure is a key target for glaucoma treatments. Nonrandomized studies in healthy volunteers and glaucoma patients have shown short‐term reductions in intraocular pressure with oral, topical eye drops, and intravenous cannabinoids,suggesting the potential for therapeutic benefit. A good‐quality systemic review identified a single small trial that found no effect of two cannabinoids, given as an oromucosal spray, on intraocular pressure. The quality of evidence for the finding of no effect is limited. However, to be effective, treatments targeting lowerintraocular pressure must provide continualratherthan transientreductionsin intraocular pressure. To date, those studies showing positive effects have shown only short‐term benefit on intraocular pressure (hours), suggesting a limited potential for cannabinoids in the treatment of glaucoma.
There is limited evidence that cannabis and oral cannabinoids are effective in increasing appetite and decreasing weight loss associated with HIV/AIDS.
There does not appear to be good‐quality primary literature that reported on cannabis or cannabinoids as effective treatments for AIDS wasting syndrome.
There is limited evidence (a single, small fair‐quality trial) that nabilone is effective for improving symptoms of posttraumatic stress disorder
A single, small crossover trial suggests potential benefit from the pharmaceutical cannabinoid nabilone. This limited evidence is most applicable to male veterans and contrasts with non‐ randomized studies showing limited evidence of a statistical association between cannabis use (plant derived forms) and increased severity of posttraumatic stress disorder symptoms among individuals with posttraumatic stress disorder. There are other trials that are in the process of being conducted and if successfully completed, they will add substantially to the knowledge base.
There is insufficient evidence that cannabinoids are an effective treatment for symptoms associated with amyotrophic lateral sclerosis.
Two small studies investigated the effect of dronabinol on symptoms associated with ALS. Although there were no differences from placebo in either trial, the sample sizes were small, the duration of the studies was short, and the dose of dronabinol may have been too small to ascertain any activity. The effect of cannabis was not investigated.
There is insufficient evidence to support or refute the conclusion that dronabinol is an effective treatment for the symptoms of irritable bowel syndrome.
Some studies suggest that marijuana in the form of cannabidiol may be beneficial in the treatment of inflammatory bowel diseases, including Crohn's disease.
There is insufficient evidence that cannabinoids are an effective treatment for the motor system symptoms associated with Parkinson's disease or the levodopainduced dyskinesia.
Evidence suggests that the endocannabinoid system plays a meaningful role in certain neurodegenerative processes; thus, it may be useful to determine the efficacy of cannabinoids in treating the symptoms of neurodegenerative diseases. Small trials of oral cannabinoid preparations have demonstrated no benefit compared to a placebo in ameliorating the side effects of Parkinson's disease. A seven‐patient trial of nabilone suggested that it improved the dyskinesia associated with levodopa therapy, but the sample size limits the interpretation of the data. An observational study demonstrated improved outcomes, but the lack of a control group and the small sample size are limitations.
There is substantial evidence that oral cannabinoids are an effective treatment for improving patient‐reported multiple sclerosis spasticity symptoms, but limited evidence for an effect on clinician‐measured spasticity.
Based on evidence from randomized controlled trials included in systematic reviews, an oral cannabis extract, nabiximols, and orally administered THC are probably effective for reducing patient‐reported spasticity scores in patients with MS. The effect appears to be modest. These agents have not consistently demonstrated a benefit on clinician‐measured spasticity indices.
The qualifying physician has provided the patient or the patient's parent or legal guardian a summary of the current research on the efficacy of marijuana to treat the patient's medical condition.
The summary is in the office and on Compassionate Healthcare of Florida's website.
The qualifying physician has provided the patient or the patient's caregiver a summary of
the current research on the efficacy of marijuana to treat the patient's terminal condition.
There is substantial evidence that cannabis is an effective treatment for chronic pain in adults.
The majority of studies on pain evaluated nabiximols outside the United States. Only a handful of studies have evaluated the use of cannabis in the United States. and all of them evaluated cannabis in flower form provided by the National Institute on Drug Abuse. In contrast, many of the cannabis products that are sold in state‐regulated markets bear little resemblance to the products that are available for research at the federal level in the United States. Pain patients also use topical forms. While the use of cannabis for the treatment of pain is supported by well controlled clinical trials, very little is known about the efficacy, dose, routes of administration, or side effects of commonly used and commercially available cannabis products in the United States.
Exposures to tobacco smoke and household air pollution consistently ranks among the top risk factors not only for respiratory disease burden but also for the global burden of disease. Given the known relationships between tobacco smoking and multiple respiratory conditions, one could hypothesize that long‐term cannabis smoking leads to similar deleterious effects of respiratory health, and some investigators ague that cannabis smoking may be even more harmful that of tobacco smoking. Data collected from 15 volunteers suggest that smoking one cannabis joint can lead to four times the exposure to carbon monoxide and three to five times more tar deposition than smoking a single cigarette.
There is moderate evidence of a statistical association between acute cannabis use and impairment in the cognitive domains of learning, memory, and attention.
There is limited evidence of a statistical association between sustain abstinence form cannabis use and impairments in the cognitive domains of learning, memory, and attention.
There is limited evidence of a statistical association between cannabis use and impaired academic achievement and education outcomes.
There is limited evidence of a statistical association between cannabis use and increased rates of unemployment and/or low income.
There is limited evidence of a statistical association between cannabis use and impaired social functioning or engagement in developmentally appropriate social roles.
Marijuana, like some other brain‐altering substances, can be addictive. Nearly one in 10 marijuana users will become addicted. Starting to use marijuana at a younger age can lead to a greater risk of developing a substance use disorder later in life. Adolescents who begin using marijuana before age 18 are four to seven times more likely than adults to develop a marijuana use disorder.
Smokable marijuana has infectious risks that are not present in processed products. Certain molds and mildews can contaminate marijuana plants during growing, processing, storage in dispensaries and in patient homes. These contaminates can pose health risks, particularly to those who are immunosuppressed due to their disease state and treatments. While the State of Florida requires third party testing you should still inspect your product.
Exposures to tobacco smoke and household air pollution consistently ranks among the top risk factors not only for respiratory disease burden but also for the global burden of disease. Given the known relations ships between tobacco smoking and multiple respiratory conditions, one could hypothesize that long‐term marijuana smoking leads to similar deleterious effects of respiratory health, and some investigators ague that marijuana smoking may be even more harmful that of tobacco smoking.
You should never smoke medical marijuana around other family members, especially children and any household guests. You should smoke outside to allow adequate ventilation and to mitigate the dangers of secondhand and thirdhand smoke to others. Marijuana should never be smoked inside vehicles or other small spaces that children will occupy even if the children are not present at the time the product is consumed.
If you use oxygen or have others in your household who use oxygen you should not smoke marijuana or any other combustible material in the vicinity of where the oxygen is in use due to the risk of fire and explosion.
I have been given instructions or discussed guidance on self‐ dosing with my qualified physician if permitted to do so.
Dr. Cipriani also informed me of the risks, complications, and expected benefits of any recommended treatment, including its likelihood of success and failure. I acknowledge that Dr. Cipriani informed me of any alternatives to the recommended treatment, including the alternative of no treatment, and the risks and benefits. Dr. Cipriani has explained the information in this consent form about the medical use of marijuana